It has been a bad tip so far but management chance at Concepta (CPT) marks a turning point. First Matthew Walls, the CEO is going. Now we have the appointments of Penelope ("Penny") McCormick as Chief Executive and Lyn Rees as a Non-Executive Director”. It is emphasised;
Concepta (CPT) has announced results for the first half of 2019 and a “first myLotus® UK Fertility Clinic collaboration”…
Concepta (CPT) has announced its calendar 2018 results which are truly ghastly. But that is all rear view mirror stuff and so at 3.7p the shares are, we suggest, a gamble but a BUY.
Nine days ago Concepta (CPT) was pushing aggressively at UK Investor - having just re-announced a deal with Boots - and mug punters responded, paying up to 3.75p to buy shares in the market. Last week I was made an insider. Apparently two big funds were desperate for shares and a placing to raise £2 million was underway...
The great success that was the 2019 Global Group UK Investor Show saw three 'Dragon's Den' sessions where a number of CEOs each gave a 1 minute (well, supposed to be!) pitch and three 'Dragons' at each session each picked a stock for a £1,000 investment. These have now been purchased, so what were the picks (& can 12 year-old Leela show the other dragons how intelligent investing is done these days)?...
We've noted that the new boss of Concepta (CPT), Matthew Walls, is a class act and he is showing it. Costs have been cut, the Chinese malarkey ended and the focus has been on monetising the MyLotus kit, which tells women exactly when the time is right to get up the duff. The reviews of MyLotus from women who have used it have been rave reviews. The question was: how to get it to market?...
This did not take long. CE-Mark approval on Monday, UK launch of Mylotus this weekend coming. Concepta (CPT) and its new boss Matthew Walls have been hard at work...
The China gambit did not work out too well. But Concepta (CPT) has a new – very well regarded – chairman in Matthew Walls, its balance sheet has been sorted by a placing and now we are on the verge of real sales and a ramp up towards and into profitability. For the company has now announced that it has received UK CE-Mark certification for its myLotus branded products for women's fertility.
July-joined Chairman of women's fertility home test platform company Concepta (CPT), Matthew Walls is “pleased to report the half year results for the six months to 30 June 2018”. He shouldn’t be…
Tom Winnifrith was an insider on this one but opted not to participate in the placing after all the grief he got for taking part on the Premaitha (NIPT) placing at 4.5p a couple of months ago. Premaitha shares are now 9.9p and that is what you may wish to consider.
Concepta (CPT) has announced results for 2017, emphasising “although progress has been slower than anticipated, we have built robust foundations in China and are well on our way to launching in the EU”…
Maybe the idiom is a bad one but it is meant to signify that Concepta (CPT) is making steady progress towards a real lift off in sales and profits. The latest news is from the UK and is that it has achieved ISO13485 certification for its manufacturing site in Doncaster. So what you say?
Concepta (CPT) has made an announcement commencing that it “is pleased to announce that it showcased its myLotus products at the Manchester Fertility Show on 24 and 25 March 2018”. Not exactly a groundbreaking occurrence!... but the company also “announced the forthcoming launch of its myLotus products in the UK at the event”…
Concepta (CPT) has always had a twin track model for rolling out MyLotus in China - direct to hospitals (B2B) and direct to individual punters (B2C). On the latter front we now have news.
Tom Winnifrith noted in a weekend bearcast that he was very bullish on Concepta (CPT) HERE. He also discussed Optibiotix (OPTI), Falanx (FLX) and others in the same podcast. For the avoidance of doubt, he was bullish on them too! Concepta has now served up good news to start to justify Tom's faith.
Concepta (CPT) has removed an unwanted duplicated cost by letting go of Beaufort Securities as its joint broker, leaving Novum as its sole broker. That's the good news. The less good news came on the last trading day before Christmas when we were told;
I have also covered my extreme annoyance with Concepta (CPT) in Bearcast HERE. Last week it had a profit warning thanks to a new order for £600,000 having been received but not being able to be booked until Q1 2018. Hence there was a 2017 miss. That saw the shares go down. There is now a placing and at the same time we were told that this order would now be booked in Q4 2017. Surely that unwinds the profits warning.
This is not perfect. But it's not a disaster. Far from it. You really would have to expect a small placing from Concepta (CPT) though after this statement.
Beaufort Securities is house broker to AIM-listed Concepta (CPT) so you may prefer to take what follows with a pinch of salt. Also worthy of note is that it is owned by FIML (which is owned by a trust for Tom Winnifrith’s dependents) and just to keep Tom Winnifrith happy, here is what Beaufort has to say on yesterday’s disappointing Trading and Order update which he covered in yesterday’s Bearcast when he suggested waiting for the placing expected to follow before piling in.
Many folks seemed to think that Concepta's (CPT) next announcement would be a (lack of) profits warning and/or a placing and the shares have been sold down on that basis. Oh ye of little faith.
Declarations first: a) at 11p offer the shares are back at the price at which Concepta (CPT) came to AIM via an RTO in July of last year. It has clearly not delivered as rapidly as we would have liked b) We invested at the RTO and have not sold any of our shed load of shares. Results for the half calendar year came out last week and, speaking bluntly, the numbers do not look that great. In fact they look piss poor. It reported sales of zero, a loss of £1.15 million and ended the period with cash of £1.235 million. So far less than dazzling right? But....
Following the receipt of its first sales order, totalling £225,000, for its myLotus fertility product from partner in China, HuanZhong Biotech Co.Ltd, Concepta (CPT) has now announced it has made its first shipment of products to China and appointed a founding member of the company as Head of China Operations…
It is good to see a CEO putting his money where his mouth is and the share purchase by Erik Henau should also scotch the silly rumours that a placing is imminent. The Concepta (CPT) head honcho has purchased 80,000 shares at 12.175p. He now owns 293,333 shares so in that context this is a decent purchase. We'd hope to see more boardroom buying soon but expect also to see more hard news on order flow very soon.
Let's start with the bad news. It really should not be a surprise given the lack of orders announced (until now!) but Concepta (CPT) has confirmed that it will miss full year 2017 sales forecasts. That is the bad news. It has launched a new product and it is a few months behind schedule. These things happen. But...
Shares in Concepta (CPT) trade at 11.875p mid this morning but are according to house broker Beaufort worth 22p. The house broker is biased but the note it has published is interesting for its - conservative - updated forecasts. If the broker is right then in just over six months time these shares will be trading on a 1 year out PE of less than 6 which is insane for a growth play. Judge for yourself. we own shed loads of these shares are will not be selling at anywhere near this price.
Concepta (CPT) has announced major news. But whichever fucktards are paid £5,000 a month for writing its press releases have done their best to bollocks it up. Step forward Yellow Jersey PR, a haven for the morally bankrupt or intellectually challenged. Anyhow, Concepta has announced its first Chinese distributor.
Concepta (CPT) has been a slow burner but we are well ahead on this share tip with the shares now at 16.6p-17p.Last autumn that it was about to sell its MyLotus kits in China and since then it has appointed a country manager and huffed and puffed but there are no sign of those sales. But you won't need to wait long. There are fireworks coming soon.
Concepta (CPT) wants to know why its shares are nor racing away although having tipped this at an 11p offer we are, at 16.5p, well up.? Simple. It announced last autumn that it was about to sell its MyLotus kits in China and since then it has appointed a country manager and huffed and puffed but there are no sign of those sales. And against that background after calendar 2016 results the shares are just 16.5p mid. But before you sell hang on a second...the shares are actually a stonking buy if yoiu can get them at 16p or underand here is why.
In this video from the storming success that was the 2017 UK Investor Show, Erik Henau, CEO, and Adam Reynolds, Chairman, of Concepta (CPT), are at the podium. And make sure that you keep April 21 2018 free for next year's UK Investor Show.
Concepta (CPT) has announced a deal that will enhance its fertility product MyLotus with an added stress test. Being stressed out can be a real issue when a chap is trying to get his Mrs up the duff.
Concepta (CPT) has announced that it has secured ISO13485 accreditation which is a key step in attaining its CE marking for its 'myLotus' product for unexplained infertility.
I sat down with Adam Reynolds, the shellmeister today and recorded a string of podcasts. This one is on Concepta (CPT) a stock we own. The shares are 16p-17p. IMHO they should be closer to 30p. The next six months will see masses of news and real, material, sales and that will, I'm sure, drive a real re-rating of the shares. Listen to what Adam says...
Fresh from opening manufacturing facilities in China in late September, Concepta (CPTA) has announced that it has taken on a 10 year lease on a site in Doncaster in the grim North of England to manufacture in the UK. It will be cheap up there.
Concepta (CPT) has announced that it has issued 464,674 shares following the exercise of warrants - something we warned you about last week. That brings in £34,851 which is frankly neither here not there. Around 10% of that cash came from the exercise of warrants by FIML and my pension fund. Neither are selling at anything like this price although the shares are well up on a 14p offer share tip.
We tipped these shares at a 12p offer - they are now 19.5p-21p but hang on tight. We aim to be selling at 25p+ very soon. But before then an urgent reminder for long term holders: warrants! Deadline 6 October.
Concepta (CPT) has announced that it has signed a deal with a Chinese company, Huanzhong Biotech Limited ( HZ) to to assemble and package Concepta's 'My Lotus' fertility product. My Lotus already has regulatory clearance and so this paves the way for a launch very soon indeed.
Hello Share Squaddies. May I bring to your attention another medical outfit which has a very encouraging market to have a go at. The firm is Concepta (CPT) and it has produced something it calls MyLotus. These are clever devices which test fertility in women, as well as being an indicator of pregnancy.
Concepta (CPT) the latest Adam Reynolds healthcare RTO on AIM has announced interim result which are pretty academic. The company is a developer of a platform and suite of products targeted at the personalised mobile health market with a primary focus on women's fertility and specifically unexplained infertility.
Investment Case: The AIM admission of Concepta (CPT) a couple of weeks ago was through a reverse takeover of shellmeister (Adam Reynolds)-saved Frontier Resources International (FRI). We backed Reynolds when he became involved in Frontier, but despite his track-record, then was clearly somewhat speculative as we awaited a deal to be delivered. Now it has and it looks like Reynolds has delivered another promising one…
Frontier Resources (FRI) is no more. It is now Concepta (CPT), new shares for the RTO, open offer and placing have been issued and the shares have undergone a 250-1 consolidation.
Search ShareProphets |
Recent Comments |